We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 3

1.
Figure 2

Figure 2. From: Efficacy of low-dose topical mitomycin C treatment for primary acquired melanosis.

Diffuse primary acquired melanosis with atypia on the bulbar and palpebral conjunctiva of patient 1 before treatment with topical mitomycin C (panels A and B) and after three cycles of mitomycin C 0.02%, four times daily for 10 days separated by 21 days between courses (panels C and D).

Susan Hung, et al. BMJ Case Rep. 2009;2009:bcr12.2008.1409.
2.
Figure 1

Figure 1. From: Efficacy of low-dose topical mitomycin C treatment for primary acquired melanosis.

Pathologic diagnosis (200×). The fornix of patient 1 displays numerous melanocytes, some with atypia, that lie in the deeper layers of the epithelium with a few extending into the more superficial layers (panel A). The limbus of patient 2 shows atypical cells that extend from the surface to the deep margin of the epithelium and occasional cells show fine granules in the cytoplasm (panel B).

Susan Hung, et al. BMJ Case Rep. 2009;2009:bcr12.2008.1409.
3.
Figure 3

Figure 3. From: Efficacy of low-dose topical mitomycin C treatment for primary acquired melanosis.

Primary acquired melanosis with atypia on the bulbar conjunctiva of patient 2 before treatment with topical mitomycin C (panels A and B) and after three cycles of mitomycin C 0.02%, four times daily for 10, 8 and 7 days separated by 21 days between courses (panels C and D). Blepharitis is evident both before and after treatment.

Susan Hung, et al. BMJ Case Rep. 2009;2009:bcr12.2008.1409.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk